MA44479A - Arn transrepliquant - Google Patents

Arn transrepliquant

Info

Publication number
MA44479A
MA44479A MA044479A MA44479A MA44479A MA 44479 A MA44479 A MA 44479A MA 044479 A MA044479 A MA 044479A MA 44479 A MA44479 A MA 44479A MA 44479 A MA44479 A MA 44479A
Authority
MA
Morocco
Prior art keywords
transreplicant
rna
transreplicant rna
Prior art date
Application number
MA044479A
Other languages
English (en)
Other versions
MA44479B1 (fr
Inventor
Tim Beissert
Mario Perkovic
Ugur Sahin
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MA44479A publication Critical patent/MA44479A/fr
Publication of MA44479B1 publication Critical patent/MA44479B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
MA44479A 2016-03-21 2017-03-13 Arn transrepliquant MA44479B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/056160 WO2017162265A1 (fr) 2016-03-21 2016-03-21 Arn à réplication trans
PCT/EP2017/055813 WO2017162461A1 (fr) 2016-03-21 2017-03-13 Arn à réplication trans

Publications (2)

Publication Number Publication Date
MA44479A true MA44479A (fr) 2021-04-21
MA44479B1 MA44479B1 (fr) 2021-11-30

Family

ID=55586324

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44479A MA44479B1 (fr) 2016-03-21 2017-03-13 Arn transrepliquant

Country Status (26)

Country Link
US (2) US12338448B2 (fr)
EP (2) EP3433368B1 (fr)
JP (2) JP7105193B2 (fr)
KR (1) KR102441725B1 (fr)
CN (2) CN115386596A (fr)
AU (1) AU2017236240B2 (fr)
BR (1) BR112018068391A2 (fr)
CY (1) CY1124689T1 (fr)
DK (1) DK3433368T3 (fr)
ES (1) ES2896927T3 (fr)
HR (1) HRP20211715T1 (fr)
HU (1) HUE058889T2 (fr)
IL (1) IL261327B2 (fr)
LT (1) LT3433368T (fr)
MA (1) MA44479B1 (fr)
MD (1) MD3433368T2 (fr)
MX (1) MX2018011384A (fr)
PL (1) PL3433368T3 (fr)
PT (1) PT3433368T (fr)
RS (1) RS62543B1 (fr)
RU (1) RU2752580C2 (fr)
SG (1) SG11201807378SA (fr)
SI (1) SI3433368T1 (fr)
SM (1) SMT202100634T1 (fr)
WO (2) WO2017162265A1 (fr)
ZA (2) ZA201805520B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
WO2019053012A1 (fr) * 2017-09-13 2019-03-21 Biontech Rna Pharmaceuticals Gmbh Réplicon d'arn pour la reprogrammation de cellules somatiques
US20200283497A1 (en) * 2017-09-13 2020-09-10 Biontech Cell & Gene Therapies Gmbh Rna replicon for expressing at cell receptor or an artificial t cell receptor
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US10736957B2 (en) 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
WO2020190750A1 (fr) 2019-03-15 2020-09-24 Modernatx, Inc. Vaccins à base d'arn contre le vih
WO2020264138A1 (fr) * 2019-06-27 2020-12-30 Emd Millipore Corporation Expansion cellulaire avec des vecteurs d'arn auto-réplicatifs exprimant des protéines d'immortalisation
MX2022007905A (es) 2019-12-31 2022-08-25 Elixirgen Therapeutics Inc Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.
CA3167611A1 (fr) 2020-02-13 2021-08-19 Etienne Simon-Loriere Vaccin a base d'acide nucleique contre le coronavirus sars-cov-2
KR102462990B1 (ko) * 2020-03-17 2022-11-07 에이비온 주식회사 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물
WO2022002783A1 (fr) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
GB202020063D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
GB202020061D0 (en) 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
GB202020064D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
MX2023011400A (es) 2021-03-26 2023-10-09 Glaxosmithkline Biologicals Sa Composiciones inmunogenicas.
US20240336672A1 (en) 2021-04-26 2024-10-10 Institut Pasteur Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
AU2022269877A1 (en) * 2021-05-04 2023-12-21 Mogrify Limited Cell conversion
EP4346894A1 (fr) 2021-05-24 2024-04-10 GlaxoSmithKline Biologicals S.A. Adjuvants
US12570977B2 (en) * 2021-06-12 2026-03-10 Mello Biotech Taiwan Co., Ltd. mRNA composition and production method for use in anti-viral and anti-cancer vaccines
WO2022264109A1 (fr) 2021-06-18 2022-12-22 Sanofi Vaccins multivalents contre la grippe
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
EP4387597A1 (fr) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Lyophilisation de nanoparticules lipidiques (lnp) encapsulant de l'arn et leurs formulations
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023021421A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Vaccins à base d'arn lyophilisés à faible dose et leurs procédés de préparation et d'utilisation
EP4392140A1 (fr) 2021-08-24 2024-07-03 BioNTech SE Technologies de transcription in vitro
CN115960922A (zh) * 2021-10-09 2023-04-14 吴可行 自复制rna分子设计及其应用
WO2023066874A1 (fr) 2021-10-18 2023-04-27 BioNTech SE Procédés pour déterminer les mutations permettant d'augmenter la fonction de l'arn modifié réplicable et compositions connexes et leur utilisation
EP4402150A1 (fr) 2021-10-22 2024-07-24 BioNTech SE Composés et complexes oligosaccharidiques
WO2023067121A1 (fr) 2021-10-22 2023-04-27 BioNTech SE Composés et complexes d'oligosaccharides
EP4169534A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Complexes oligosaccharides et utilisations
EP4169578A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Composés et complexes d'oligosaccharide
EP4285933A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Complexes oligosaccharides et utilisations
EP4402149A1 (fr) 2021-10-22 2024-07-24 BioNTech SE Composés et complexes d'oligosaccharides de disulfure
EP4286003A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Composés et complexes d'oligosaccharide
US20250057944A1 (en) 2021-10-22 2025-02-20 BioNTech SE Oligosaccharide complexes and uses
EP4186528A1 (fr) 2021-11-30 2023-05-31 BioNTech SE Complexes oligosaccharides et utilisations
EP4169580A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Composés et complexes d'oligosaccharide
EP4286004A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Composés et complexes d'oligosaccharide de disulfure
EP4285932A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Complexes oligosaccharides et utilisations
EP4286394A1 (fr) 2022-05-30 2023-12-06 BioNTech SE Composés et complexes d'oligosaccharide
EP4401788A1 (fr) 2021-10-22 2024-07-24 BioNTech SE Complexes oligosaccharidiques et leurs utilisations
EP4169579A1 (fr) 2021-10-22 2023-04-26 BioNTech SE Composés et complexes d'oligosaccharide de disulfure
TW202346593A (zh) 2021-11-05 2023-12-01 法商賽諾菲公司 呼吸道融合病毒rna疫苗
WO2023083434A1 (fr) 2021-11-09 2023-05-19 BioNTech SE Arn codant pour la peptidoglycane hydrolase et son utilisation pour le traitement d'une infection bactérienne
CN119095613A (zh) 2021-12-17 2024-12-06 赛诺菲 莱姆病rna疫苗
CN119522105A (zh) 2022-05-06 2025-02-25 赛诺菲 核酸疫苗的信号序列
CN119562807A (zh) 2022-05-30 2025-03-04 生物技术公司 用于递送核酸的复合物
EP4577236A1 (fr) 2022-08-22 2025-07-02 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccins contre les coronavirus
US20260096998A1 (en) 2022-09-26 2026-04-09 BioNTech SE Nucleic acid complexes and uses thereof
WO2024086549A1 (fr) * 2022-10-17 2024-04-25 The University Of North Carolina At Chapel Hill Alphavirus chimériques pour évolution dirigée
WO2024083345A1 (fr) 2022-10-21 2024-04-25 BioNTech SE Procédés et utilisations associés à des compositions liquides
EP4605010A1 (fr) 2022-10-21 2025-08-27 BioNTech SE Complexes d'acide nucléique et leurs utilisations
AU2023374764A1 (en) 2022-11-04 2025-06-19 Sanofi Pasteur Inc. Respiratory syncytial virus rna vaccination
AU2023383367A1 (en) 2022-11-18 2025-05-29 Trustees Of Boston University Self-replicating rna and uses thereof
EP4634207A1 (fr) 2022-12-15 2025-10-22 Sanofi Pasteur Inc. Enzymes de coiffage recombinantes d'arnm
WO2024133160A1 (fr) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Compositions pour le traitement de l'hépatite b
WO2024133550A1 (fr) 2022-12-22 2024-06-27 Vector Biopharma Ag Système d'auto-amplification eucaryote
EP4669348A1 (fr) 2023-02-24 2025-12-31 BioNTech SE Compositions immunogènes
JP2026504797A (ja) 2023-03-02 2026-02-10 サノフィ・パスツール クラミジア（Ｃｈｌａｍｙｄｉａ）の治療に使用するための組成物
EP4442276A1 (fr) 2023-04-07 2024-10-09 Institut Pasteur Anticorps combinés contre les sarcovirus et leurs utilisations
WO2024231727A1 (fr) 2023-05-05 2024-11-14 Sanofi Compositions destinées à être utilisées dans le traitement de l'acné
TW202508620A (zh) 2023-05-10 2025-03-01 尼可拉斯 克拉克 呼吸道mrna組合疫苗
WO2024236192A1 (fr) 2023-05-17 2024-11-21 Institut Pasteur Hétérodimère de protéines a16 et g9 de poxvirus en tant qu'agent immunogène
EP4474015A1 (fr) 2023-06-05 2024-12-11 Veterna Srl Pharmacon de vaccin à arn de type noda et sa production et ses utilisations
CN121889496A (zh) 2023-07-19 2026-04-17 赛诺菲 牙龈卟啉单胞菌抗原构建体
WO2025027089A1 (fr) 2023-08-01 2025-02-06 BioNTech SE Thioplipides ionisables et leurs utilisations
WO2025026545A1 (fr) 2023-08-01 2025-02-06 BioNTech SE Thioplipides ionisables et utilisations associées
WO2025052001A1 (fr) 2023-09-07 2025-03-13 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire
EP4520334A1 (fr) 2023-09-07 2025-03-12 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire
CN122055450A (zh) * 2023-10-16 2026-05-15 韩国生命工学研究院 用于改善蛋白质翻译效率的RNA结构、包含其的mRNA结构及其用途
WO2025096982A1 (fr) * 2023-11-02 2025-05-08 Amplitude Therapeutics, Inc. Arn transamplifiant comportant des nucléobases chimiquement modifiées
WO2025124711A1 (fr) 2023-12-13 2025-06-19 BioNTech SE Compositions de glycolipides
TW202525287A (zh) 2023-12-21 2025-07-01 德商拜恩技術運輸科技有限責任公司 可離子化脂質
WO2025134066A1 (fr) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Lipides ionisables
WO2025153707A1 (fr) 2024-01-19 2025-07-24 Spikimm Anticorps monoclonaux neutralisants à large spectre dirigés contre le sars-cov-2 et leurs utilisations
CN120379688A (zh) * 2024-01-24 2025-07-25 南京金斯瑞生物科技有限公司 一种自复制rna及其用途
WO2025217136A2 (fr) * 2024-04-08 2025-10-16 Amplitude Therapeutics, Inc. Arn trans-amplificateurs codant pour des immunomodulateurs
EP4656648A1 (fr) 2024-05-31 2025-12-03 Consejo Superior De Investigaciones Científicas Composés immunomodulateurs à base de thiourée et d'urée et leurs utilisations
WO2025262460A1 (fr) 2024-06-21 2025-12-26 BioNTech SE Compositions lipidiques pour l'administration d'acides nucléiques
WO2026008743A1 (fr) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Polymère polyanionique soluble dans l'eau en tant qu'adjuvant pour acide nucléique formulé par un support
WO2026033380A1 (fr) 2024-08-05 2026-02-12 BioNTech SE Processus de préparation de complexes oligosaccharidiques
EP4696782A1 (fr) 2024-08-14 2026-02-18 Starvax One B.V. Replicons d'arn divise ameliores

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9908967B1 (pt) * 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
KR20020013508A (ko) 1999-03-09 2002-02-20 유니버시티 오브 플로리다 외래 서열을 발현시키기위한 다성분 ｒｎａ 벡터 시스템
CN1250731C (zh) 2000-08-29 2006-04-12 惠氏控股公司 正链rna病毒复制子颗粒的包装
AU2002303330B2 (en) * 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
US20030232324A1 (en) 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
US7045335B2 (en) 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
EP1490494A1 (fr) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Procede pour concevoir des sequences d'acides nucleiques de synthese pour l'expression optimale de proteines dans une cellule hote
KR101518309B1 (ko) * 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
ES2647491T3 (es) * 2004-05-21 2017-12-21 Novartis Vaccines And Diagnostics, Inc. Vectores del alfavirus para las vacunas del virus de la gripe
WO2008119827A1 (fr) * 2007-04-02 2008-10-09 Fit Biotech Oy Produits de synthèse transréplicases
EP2167523B1 (fr) 2007-06-19 2014-07-23 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Synthèse et utilisation d'analogues de phosphorothioate anti-inverse de la coiffe d'arn messager
DK2183368T3 (en) * 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
EP2185591B1 (fr) 2007-08-20 2014-05-14 Glaxo Group Limited Procédé de production
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2281579A1 (fr) 2009-08-05 2011-02-09 BioNTech AG Composition de vaccin comportant un ADN modifié 5'-Cap
EP3449910A1 (fr) 2010-07-06 2019-03-06 GlaxoSmithKline Biologicals S.A. Des émulsions cationiques huile-en-eau
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
US11291635B2 (en) * 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
TR201908635T4 (tr) 2010-08-31 2019-07-22 Glaxosmithkline Biologicals Sa Protein kodlayıcı rna?nın lipozomal verilmesine uygun lipitler.
BR112013004879A2 (pt) 2010-08-31 2018-04-24 Novartis Ag lipossomas pequenos para entrega de rna que codifica imunogénio
WO2012031043A1 (fr) 2010-08-31 2012-03-08 Novartis Ag Liposomes pégylés pour l'apport d'arn codant pour un immunogène
EP3520813B1 (fr) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Plateformes de délivrance d'antigènes
AU2012280901B2 (en) 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
EP3854413A1 (fr) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Compositions de combinaisons immunogènes et utilisations de celles-ci
RU2649133C2 (ru) 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
EP4014966A1 (fr) 2011-07-06 2022-06-22 GlaxoSmithKline Biologicals S.A. Liposomes ayant un rapport n:p utile pour délivrance de molécules d'arn
SG11201400250UA (en) 2011-08-31 2014-03-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
US20140271829A1 (en) 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
CN107875382B (zh) 2011-11-11 2024-03-08 变异生物技术公司 用于治疗巨细胞病毒的组合物和方法
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
MX357803B (es) 2012-03-27 2018-07-24 Curevac Ag Moléculas de ácido nucleico artificiales.
CA2859452C (fr) 2012-03-27 2021-12-21 Curevac Gmbh Molecules d'acide nucleique artificielles pour une expression proteique ou peptidique amelioree
WO2014071963A1 (fr) 2012-11-09 2014-05-15 Biontech Ag Procédé pour l'expression d'arn cellulaire
WO2014170493A2 (fr) * 2013-04-19 2014-10-23 Novartis Ag Vecteur d'alphavirus
WO2016005004A1 (fr) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilisation de séquences d'adn codant pour une séquence poly (a)
US20200362313A1 (en) 2017-09-13 2020-11-19 Biontech Rna Pharmaceuticals Gmbh Method of enhancing rna expression in a cell

Also Published As

Publication number Publication date
JP2019509048A (ja) 2019-04-04
AU2017236240A1 (en) 2018-09-20
WO2017162461A1 (fr) 2017-09-28
MX2018011384A (es) 2019-02-13
RU2018131783A (ru) 2020-04-22
RU2018131783A3 (fr) 2020-07-14
CN109328233B (zh) 2022-10-11
DK3433368T3 (da) 2021-11-15
ZA201805520B (en) 2019-11-27
US20200299724A1 (en) 2020-09-24
IL261327B2 (en) 2024-08-01
EP3433368A1 (fr) 2019-01-30
JP7105193B2 (ja) 2022-07-22
MD3433368T2 (ro) 2021-12-31
EP3964584A1 (fr) 2022-03-09
HUE058889T2 (hu) 2022-09-28
RU2752580C2 (ru) 2021-07-29
MA44479B1 (fr) 2021-11-30
ZA201905396B (en) 2021-03-31
IL261327B1 (en) 2024-04-01
IL261327A (en) 2018-10-31
SG11201807378SA (en) 2018-10-30
SMT202100634T1 (it) 2022-01-10
CA3017285A1 (fr) 2017-09-28
KR102441725B1 (ko) 2022-09-08
KR20180127360A (ko) 2018-11-28
US20250290095A1 (en) 2025-09-18
SI3433368T1 (sl) 2022-01-31
US12338448B2 (en) 2025-06-24
CY1124689T1 (el) 2022-07-22
ES2896927T3 (es) 2022-02-28
AU2017236240B2 (en) 2022-11-17
RS62543B1 (sr) 2021-12-31
JP7421256B2 (ja) 2024-01-24
EP3433368B1 (fr) 2021-10-06
BR112018068391A2 (pt) 2019-01-15
HRP20211715T1 (hr) 2022-02-18
PL3433368T3 (pl) 2021-12-27
CN115386596A (zh) 2022-11-25
CN109328233A (zh) 2019-02-12
JP2022020634A (ja) 2022-02-01
LT3433368T (lt) 2021-11-25
PT3433368T (pt) 2021-11-15
WO2017162265A1 (fr) 2017-09-28

Similar Documents

Publication Publication Date Title
DK3433368T3 (da) Transreplikerende rna
MA47680A (fr) Arn thérapeutique
EP3502950A4 (fr) Multiplicateur-accumulateur
DK3405050T3 (da) Børnesikret snusbeholder
EP3440949A4 (fr) Inhalateur d'arôme
EP3446605A4 (fr) Aspirateur à main
DK3436823T3 (da) Antigen-array
EP3455498A4 (fr) Injecteur de distribution de carburant
EP3445380C0 (fr) Bactériothérapie
EP3450133A4 (fr) Procédé de moulage par soufflage de liquide
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
EP3436590A4 (fr) Arn de transépissage (tsrna)
EP3402022A4 (fr) Pince-fil
EP3465295A4 (fr) Empilement de polariseurs
DK3445708T3 (da) Stigbøjle
LT3632828T (lt) Ritė
EP3402021A4 (fr) Pince-fil
DK3452590T3 (da) Plademagnet
DK3509963T3 (da) Pallecontainer
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
EP3399976C0 (fr) Amphophiles de benzothiazole
EP3473285A4 (fr) Injecteur
DE112017000734A5 (de) Glycolsensor